| Brand | Active substance | Approved use | Administration | Since | Information |
|---|---|---|---|---|---|
| Renvia™ | risalimab | Active lupus nephritis in adults | Intravenous, every 4 weeks | 2024 | Prescribing info |
| Colevra™ | tolvaritinib | Moderate-to-severe ulcerative colitis | Oral, once daily | 2023 | Prescribing info |
| Zenatide™ | emsagludide | Type 2 diabetes with cardiovascular risk | Subcutaneous, weekly | 2022 | Prescribing info |
| Oncavis™ | daratuximab vedotin | HER2-positive metastatic breast cancer, 2L+ | Intravenous, every 3 weeks | 2021 | Prescribing info |
| Neurast™ | pelodapsen | Relapsing multiple sclerosis | Oral, twice daily | 2020 | Prescribing info |
| Vaxeria™ RSV | — | RSV prevention in adults aged 60 and over | Single intramuscular dose | 2025 | Prescribing info |
| Fabrilex™ | agalsidase beta-bx | Fabry disease in adults and adolescents | Intravenous, every 2 weeks | 2019 | Prescribing info |
Product safety & pharmacovigilance
Monitoring a medicine does not stop at approval. Our global pharmacovigilance team reviews every reported event, runs periodic benefit–risk assessments, and updates labelling with regulators when the evidence changes.
How to report a side effect
Report suspected side effects to Baxtra Drug Safety at drugsafety@baxtra.com or +1 (800) 555-0142, and to your national regulator — in the US, the FDA MedWatch program; in the EU, your national competent authority.
Product quality complaints
If a product appears damaged, discoloured or otherwise not as expected, keep the packaging and contact quality@baxtra.com with the batch number.
Counterfeit medicines
Only obtain Baxtra medicines from licensed pharmacies. Report suspected counterfeit product to productprotection@baxtra.com.
Supply and shortages
Current supply status by market is published monthly and shared with health authorities. Contact your Baxtra market affiliate for country-specific information.
Patient assistance
Income-based support for eligible patients in the US and co-pay assistance where permitted.
Check eligibilityMedical information
Scientific questions from healthcare professionals, answered by our medical information team.
Ask a questionGlobal access
Tiered pricing and not-for-profit supply in low- and middle-income countries.
Our access approach